<DOC>
	<DOCNO>NCT01012102</DOCNO>
	<brief_summary>To compare 3 dos EMD 640744 administer subcutaneous injection combination Montanide® ISA 51 VG regard immunological efficacy . The primary target variable immune response assess ELISPOT week 17 vaccination EMD 640744 Montanide® ISA 51 VG .</brief_summary>
	<brief_title>EMD 640 744 Montanide ISA 51 VG Administered Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Male female subject ≥18 year age Signed write informed consent Histologically cytologically document metastatic locally advanced survivinexpressing solid tumor establish therapy exists Disease must measurable RECIST criterion evaluable clinical , radiographic , laboratory criterion establish give tumor entity Expressing least one follow HLA allele : HLAA1 , A2 , A3 , A24 , B7 assess HLAgenotyping ECOG performance status ≤1 , estimate life expectancy least 3 month Adequate hematological function define WBC ≥3 x 10x9/L , lymphocyte count ≥0.5 x 10x9/L , hemoglobin ≥10 g/dL , platelet count ≥100 x 10x9/L Adequate blood coagulation parameter define aPTT INR ≤ 1.5 x ULN Adequate renal function define serum creatinine ≤2 x ULN Adequate hepatic function define total bilirubin ≤2 x ULN AST ALT level ≤2.5 x ULN ( subject liver metastasis ≤5 x ULN ) Effective contraception female male subject risk conception exists Treatment another clinical study within past 30 day prior first administration study treatment Previous treatment investigational anticancer vaccine Requirement concurrent treatment nonpermitted drug Active significant autoimmune disease ( exception vitiligo ) Receipt allogeneic stem cell transplantation Significant acute chronic infection ( e.g . viral hepatitis , HIV ) Primary brain tumor brain metastasis ( exception brain metastasis stable irradiation surgically resect brain metastasis subject asymptomatic ≥6 month ) Rapidly progressive disease ( e.g . tumor lysis syndrome ) Radiotherapy , chemotherapy , surgery ( exclude prior diagnostic biopsy ) , immunotherapy investigational drug within 30 day start study treatment Pregnancy lactation Active drug alcohol abuse Known hypersensitivity study treatment component Any significant disease , Investigator 's opinion , exclude subject study ; question criterion , Investigator contact sponsor . Persisting toxicity relate prior therapy ≥grade 2 National Cancer InstituteCommon Terminology Criteria For Adverse Events version 3.0 Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>EMD 640744</keyword>
	<keyword>Montanide</keyword>
	<keyword>Advanced solid tumour</keyword>
</DOC>